[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628565":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":13,"locations":19,"responsibleParty":37,"collaborators":10,"id":41,"slug":10,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":10,"eligibilityCriteria":45,"healthyVolunteers":42,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":10,"studyType":52,"phases":10,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Shanghai East Hospital","OTHER",[8,11],{"label":9,"type":10,"description":10,"interventionNames":10},"control group",null,{"label":12,"type":10,"description":10,"interventionNames":10},"MASH group",[14],{"name":15,"role":16,"phone":17,"phoneExt":10,"email":18},"Ting Mao, Bachelor","CONTACT","134-8797-5691","13487975691@qq.com",[20],{"facility":5,"status":21,"city":22,"state":23,"zip":24,"country":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"RECRUITING","Shanghai","Shanghai Municipality","200120","China",{"type":27,"coordinates":28},"Point",[29,30],121.45806,31.22222,{"lat":30,"lon":29},[33],{"name":34,"role":16,"phone":35,"phoneExt":10,"email":36},"Zengguang Xu","+86-021-38804518-22198","tongjiyixue@126.com",{"type":38,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Mingyi XU","Chief Physician","100628565",false,"NCT07463287","High-Risk Transcriptome Molecular Prediction Study of MASH-Associated Colorectal Polyps","Inclusion Criteria:\n\n1. Diagnosis of MAFLD conforms to the \"Guidelines for the Prevention and Treatment of Non-alcoholic Fatty Liver Disease\" (2018 Edition);\n2. Male or female patients aged 18-70 years;\n3. Signed informed consent form and explanation of the specific study protocol.\n\nExclusion Criteria:\n\n1. Chronic liver disease due to other etiologies (alcoholic, viral, autoimmune, drug-induced, etc.), decompensated cirrhosis, primary liver cancer;\n2. Underlying diseases of other vital organs (heart, kidney, lung, etc.) and bleeding disorders;\n3. Individuals lacking legal capacity or with poor insight.","ALL","18 Years","70 Years",{"count":50,"type":51},100,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the molecular characteristics of colorectal polyps in patients with metabolic dysfunction-associated steatohepatitis (MASH) compared to individuals without fatty liver, and to identify potential transcriptomic biomarkers for high-risk polyps. The main questions it aims to answer are: What are the key gene expression differences in adenomatous polyps between MASH patients and non-fatty liver individuals? Can specific high-risk transcriptional molecules in plasma and polyp tissue serve as biomarkers for MASH-related colorectal polyps? Participants already scheduled for colonoscopic polypectomy as part of their routine care will provide a small portion of their polyp tissue, residual plasma from standard blood tests, and allow use of their stored pathological slides for research; they will also be followed up every six months.",[55],"MASH - Metabolic Dysfunction-Associated Steatohepatitis",[57,58],"colorectal polyps","MASH","2026-03-10",{"date":61,"type":62},"2026-03-11","ACTUAL",{"date":64,"type":62},"2025-04-30",{"date":66,"type":51},"2027-04-30",{"name":5,"class":6},1]